Roche Receives FDA Approval for Tecentriq Plus Avastin in Adjuvant Hepatocellular Carcinoma

Roche today announced that the FDA has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as adjuvant treatment for adults with hepatocellular carcinoma (HCC) who are at high risk of recurrence following surgical resection or ablation. In the Phase 3 IMbrave050 trial, the combination demonstrated a statistically significant improvement in recurrence-free survival compared to active surveillance. The 2-year RFS rate was 78.5% for Tecentriq plus Avastin versus 65.1% for active surveillance. This approval provides patients with resected HCC a new adjuvant treatment option to reduce the risk of cancer recurrence.